Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac to a Three-dose Regimen of Engerix-B in Adults (PROTECT)

Next Previous
Trial Profile

A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac to a Three-dose Regimen of Engerix-B in Adults (PROTECT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B vaccine recombinant - VBI Vaccines (Primary) ; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Registrational
  • Acronyms PROTECT
  • Sponsors VBI Vaccines

    • Most Recent Events

    • 25 Jun 2023 According to a VBI vaccines media release, results form this trial were presented at the European Association for the Study of the Liver (EASL) Congress 2023.
    • 25 Jun 2023 Results presented in the Brii Biosciences Media Release.
    • 07 Jun 2023 According to a VBI vaccines media release, 3.5 year follow up results from this trial has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top